Menu Search
Equities

Roivant Sciences Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
87S:STU

Roivant Sciences Ltd

Actions
  • Price (EUR)19.33
  • Today's Change1.53 / 8.57%
  • Shares traded806.00
  • 1 Year change+85.78%
  • Beta1.2139
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

  • Revenue in USD (TTM)20.33m
  • Net income in USD-700.99m
  • Incorporated2014
  • Employees750.00
  • Location
    Roivant Sciences Ltd7Th Floor, 50 BroadwayLONDON SW1H 0DBUnited KingdomGBR
  • Phone+44 12955950
  • Websitehttp://roivant.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.